Amgen Paying $762 Million to Resolve Criminal and Civil Charges

by Admin | December 19, 2012 5:01 pm

December 19, 2012—The biotechnology company Amgen agreed today to a $762 million global settlement with the federal government that encompasses claims that the company knowingly misreported best prices and average manufacturer prices (AMPs) for several of its drugs.

A federal district judge in Brooklyn, N.Y., accepted a guilty plea by Amgen for illegally introducing a misbranded drug, Aranesp, into interstate commerce. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2012/12/amgen-paying-762-million-to-resolve-criminal-and-civil-charges/

Copyright ©2026 340binformed.org unless otherwise noted.